Supernus Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 06/04/2023
Supernus Pharmaceuticals Stock Forecast and Price Target
The average target price for Supernus Pharmaceuticals's stock set by renowned analysts in recent months is $34.00, representing a potential upside of approximately 1.4% from its last closing price if met by 2024. This estimation is based on a high estimate of $44.00 and a low estimate of $30.00. If you are interested in SUPN stock, you should also look at its competitors.
1.40% Upside
Supernus Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Supernus Pharmaceuticals has seen a decline in its Price, from $28.88 to $13.48 – a 53.33% decrease. In the next year, analysts believe that Fair Value will reach $25.63 – an increase of 90.21%. For the next nine years, the forecast is forFair Value to grow by 130.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
16
|
¥4.08k | Buy/Sell | ¥0.00 | 7.84% |
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£1.80k | Buy/Sell | £29.33 | -98.47% |
| ALKS Stock Forecast | Alkermes | Hold |
10
|
$27.11 | Buy/Sell | $0.00 | 18.04% |
| PBH Stock Forecast | Prestige Consumer Healthcare | Buy |
16
|
$58.50 | Buy/Sell | $63.50 | 16.24% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$39.09 | Buy/Sell | $79.67 | 99.54% |
Supernus Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
Supernus Pharmaceuticals's Revenue has seen growth In the last two years, going from $392.76M to $579.78M – a gain of 47.62% According to the 0 analysts polled, in the next year, Supernus Pharmaceuticals's Revenue will fall by 15.00%, reaching $492.79M. By 2030, professionals believe that Supernus Pharmaceuticals's Revenue will have decreased by 13.20%, falling to $503.27M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$46.70 | Buy/Sell | $41.00 | -5.78% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$11.03 | Buy/Sell | $12.60 | 13.33% |
| COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF56.10 | Buy/Sell | CHF0.00 | 65.54% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| COLL Stock Forecast | Collegium Pharmaceutical | Buy |
11
|
$21.63 | Buy/Sell | $27.50 | 34.07% |
| NasdaqGS:BDSI Stock Forecast | BioDelivery Sciences Internati... | - |
11
|
$5.59 | Buy/Sell | $10.00 | 78.89% |
| ANIP Stock Forecast | ANI Pharmaceuticals | Outperform |
13
|
$46.42 | Buy/Sell | $61.67 | -3.06% |
Supernus Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030
Supernus Pharmaceuticals's Free Cash Flow has decreased In the last two years, from $141.74M to $125.08M – a 11.75% drop. In the next year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $133.68M – an increase of 6.87%. The Supernus Pharmaceuticals forecast is for Free Cash Flow to reach $133.63M or grow by 6.83%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EGRX Stock Forecast | Eagle Pharmaceuticals | Outperform |
14
|
$21.53 | Buy/Sell | $50.50 | 125.27% |
| ENDP Stock Forecast | Endo International | Underperform |
14
|
$0.41 | Buy/Sell | $0.00 | 143.90% |
| ASRT Stock Forecast | Assertio Holdings | Outperform |
8
|
$5.51 | Buy/Sell | $5.83 | 8.89% |
Supernus Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Supernus Pharmaceuticals's Net Income has fallen from $113.06M to $53.42M – a 52.75% decrease. In the next year, analysts predict that Net Income will reach $100.49M – an increase of 88.12%. For the next nine years, the forecast is for Net Income to grow by 126.84%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRRX Stock Forecast | DURECT | Buy |
9
|
$4.15 | Buy/Sell | $6.50 | 44.58% |
| ACRX Stock Forecast | AcelRx Pharmaceuticals | Outperform |
6
|
$0.29 | Buy/Sell | $4.25 | 1279.31% |
| AQST Stock Forecast | Aquestive Therapeutics | Outperform |
0
|
$2.93 | Buy/Sell | $0.00 | 241.30% |
Supernus Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Supernus Pharmaceuticals's EBITDA has seen a drop from $155.23M to $139.49M – a 10.14% decrease. For next year, the 0 analysts predict EBITDA of $170.46M, which would mean an increase of 22.20%. Over the next nine years, the pros' prediction is EBITDAof $173.40M, which would mean a nine-year growth forecast of 24.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CPIX Stock Forecast | Cumberland Pharmaceuticals | - |
0
|
$2.23 | Buy/Sell | $0.00 | 10.76% |
| LCI Stock Forecast | Lannett Company | Hold |
10
|
$0.62 | Buy/Sell | $2.25 | 262.90% |
| ACOR Stock Forecast | Acorda Therapeutics | - |
5
|
$0.45 | Buy/Sell | $5.00 | 11.11% |
Supernus Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Supernus Pharmaceuticals's EBIT has gone down from $148.57M to $106.90M – a 28.05% drop. In the next year, analysts expect EBIT to reach $151.43M – an increase of 41.66%. For the next nine years, the forecast is for EBIT to grow by 49.35%.
Supernus Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Supernus Pharmaceuticals has seen a decline in its EPS, from $2.10 to $0.98 – a 53.33% decrease. In the next year, analysts believe that EPS will reach $1.86 – an increase of 90.21%. For the next nine years, the forecast is forEPS to grow by 130.99%.
Site Navigation
.jpg)